Singapore: China-based 3SBio recently announced the acquisition of Sirton pharmaceuticals from First Shangai Limited. 3SBio is China's leading biotechnology company focused on research, development, manufacturing and marketing of biopharmaceutical products.

Dr Jing Lou, chairman and CEO, 3SBio, commented, "At 3SBio we aim at expanding our footprint to key developed markets. With a team of experienced professionals and a client base of leading pharmaceutical companies, Sirton provides 3SBio with a solid base to manufacture, develop and market pharmaceutical products in Europe. We look forward to working with Sirton's management team and clients to provide safe, affordable and innovative medicines for patients across Europe."

Mr Giorgio Biella, MD, Sirton, added, "We look forward to working with 3SBio as we pursue our common goal of manufacturing high-quality medicines for international markets. 3SBio's proven R&D capabilities, global business development strategies, and strong financial position will complement Sirton's existing client relationships and manufacturing experience in Europe."

Italy-based Sirton Pharmaceuticals is a contract manufacturing company, producing injectable pharma products, including pre-filled syringes, liquid vials, freeze-dried vials and ampoules, and offers pharmaceutical development services including lyophilization process development, analytical method development and validation, stability studies and manufacturing of clinical study materials.